Editorial: Recent Advances in Potential Biomarkers for Rheumatic Diseases and in Cell-Based Therapies in the Management of Inflammatory Rheumatic Diseases

Philippe Saas; Eric Toussirot; Katarzyna Bogunia-Kubik

doi:10.3389/fimmu.2021.836119

Editorial: Recent Advances in Potential Biomarkers for Rheumatic Diseases and in Cell-Based Therapies in the Management of Inflammatory Rheumatic Diseases

Front Immunol. 2022 Jan 12:12:836119. doi: 10.3389/fimmu.2021.836119. eCollection 2021.

Authors

Philippe Saas^{1

2}, Eric Toussirot^{1

2

3

4

5}, Katarzyna Bogunia-Kubik⁶

Affiliations

¹ Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098 RIGHT, Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, Fédération Hospitalo-Universitaire INCREASE, LabEx LipSTIC, Besançon, France.
² INSERM CIC-1431, Centre d'Investigation Clinique Biothérapie, Pôle Recherche, CHU de Besançon, Besançon, France.
³ Fédération Hospitalo-Universitaire INCREASE, CHU de Besançon, Besançon, France.
⁴ Rhumatologie, Pôle PACTE (Pathologies Aiguës Chroniques Transplantation Éducation), CHU de Besançon, Besançon, France.
⁵ Département Universitaire de Thérapeutique, Université de Bourgogne Franche-Comté, Besançon, France.
⁶ Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, Poland.

No abstract available

Keywords: TNF inhibitors; biomarkers; cell-based therapy; inflammatory rheumatic diseases; psoriatic arthritis; rheumatoid arthritis; spondyloarthritis; systemic lupus erythematosus.

Publication types

Editorial
Introductory Journal Article
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Biomarkers*
Cell- and Tissue-Based Therapy / adverse effects
Cell- and Tissue-Based Therapy / methods*
Disease Management
Disease Progression
Disease Susceptibility*
Humans
Rheumatic Diseases / diagnosis
Rheumatic Diseases / etiology*
Rheumatic Diseases / metabolism*
Rheumatic Diseases / therapy*
Treatment Outcome

Substances

Biomarkers